Sun Yat-Sen Memorial Hospital | China
Author Profile
Scopus
Orcid ID
Google Scholar
EARLY ACADEMIC PURSUITS:
Saw Phei Er commenced her academic journey with a Bachelor of Biotechnology from the University of Malaysia Sabah, Malaysia, where she conducted research on the analysis of N-glycan and O-glycan uromodulin and its implications in gestational diabetic (GDM) women. She continued her pursuit of knowledge by pursuing a Ph.D., divided between the School of Life Science at Gwangju Institute of Science and Technology and the Department of Biological Sciences at Korea Advanced Institute of Science and Technology, focusing on lipid-based nanovehicles for cancer therapy.
PROFESSIONAL ENDEAVORS:
Following her doctoral studies, Saw undertook several research positions to expand her expertise. She engaged in research internships at Gwangju Institute of Science and Technology, where she synthesized A9 and A10 aptamers and gold nanoparticles. Later, she served as a Research Assistant at the University of Malaya, Malaysia, investigating gene transfer into seawater algae using biolistic guns as a defense mechanism against waterborne bacteria and viruses. Subsequently, she embarked on post-doctoral research roles at Korea Advanced Institute of Science and Technology and Brigham and Women’s Hospital, Harvard Medical School, focusing on cancer therapy and nanoparticle-based drug delivery systems.
CONTRIBUTIONS AND RESEARCH FOCUS NANO THERAPHY:
As a Professor at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Saw Phei Er continues to make significant contributions to the field of Nano Theraphy Awards and nanomedicine. Her research interests encompass the development of novel bioactive nanoparticles for targeted cancer therapy, siRNA and drug delivery using lipid-based nanoparticles, and the formulation of nanoparticle-encapsulated small biologic drug conjugates to enhance in vivo circulation and tissue penetration. Additionally, she explores nature-inspired nanomaterials for immunomodulation and cancer therapy, along with tumor-microenvironment responsive nanoparticles for effective cancer therapy.
IMPACT AND INFLUENCE:
Saw's research has garnered international recognition, evident from her numerous awards and accolades, including being named a Top 2% Most Cited Scientist in the World in 2023 and receiving the IAAM Young Scientist Award in 2022. Her work on cancer-targeting liposomes has been among the top-cited publications in the field of radio-oncology in South Korea. As the Director of the Office of Research Integrity and Vice Director of the Department of General Practice at SYSMH, she also plays a crucial role in shaping research standards and practices.
ACADEMIC CITATIONS:
With an impressive citation count of 5364 and an H-index of 40 as of March 2024, Saw Phei Er's research has made a substantial impact on the scientific community, influencing future directions in cancer therapy and nanomedicine.
LEGACY AND FUTURE CONTRIBUTIONS:
Saw's legacy lies in her pioneering work in developing innovative nanoparticle-based strategies for cancer therapy and drug delivery. Her interdisciplinary approach and commitment to translational research hold promise for significant advancements in personalized medicine and targeted cancer treatment. In the future, she aims to further expand her research endeavors, continuing to push the boundaries of nanomedicine and contribute to improved patient outcomes in oncology.
NOTABLE PUBLICATIONS: